Table of Content

"1    INTRODUCTION    40
1.1    OBJECTIVES OF THE STUDY    40
1.2    MARKET DEFINITION    40
1.2.1    INCLUSIONS & EXCLUSIONS    40
1.3    MARKET SCOPE    41
FIGURE 1    CLINICAL TRIALS MARKET    41
1.3.1    YEARS CONSIDERED FOR THE STUDY    42
1.4    CURRENCY    42
1.5    LIMITATIONS    42
1.6    STAKEHOLDERS    43
1.7    SUMMARY OF CHANGES    43
2    RESEARCH METHODOLOGY    44
2.1    RESEARCH DATA    44
FIGURE 2    RESEARCH DESIGN    44
2.1.1    SECONDARY DATA    45
2.1.2    PRIMARY DATA    46
FIGURE 3    CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES    46
2.2    MARKET SIZE ESTIMATION    47
FIGURE 4    MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET    47
FIGURE 5    MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020    48
FIGURE 6    AVERAGE MARKET SIZE ESTIMATION, 2020    48
2.3    GROWTH RATE ASSUMPTIONS/GROWTH FORECAST    50
FIGURE 7    CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2021–2026    50
FIGURE 8    CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES    51
FIGURE 9    MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH    51
2.4    MARKET BREAKDOWN AND DATA TRIANGULATION    53
FIGURE 10    DATA TRIANGULATION METHODOLOGY    53
2.5    INSIGHTS FROM PRIMARIES    54
FIGURE 11    MARKET VALIDATION FROM PRIMARY EXPERTS    54
2.6    RESEARCH ASSUMPTIONS    54
2.6.1    COVID-19 SPECIFIC ASSUMPTIONS    55
2.7    RISK ANALYSIS    55
3    EXECUTIVE SUMMARY    56
FIGURE 12    CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026 (USD BILLION)    56
FIGURE 13    CLINICAL TRIALS MARKET, BY THERAPY AREA, 2021 VS. 2026 (USD BILLION)    57
FIGURE 14    CLINICAL TRIALS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)    57
FIGURE 15    CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021 VS. 2026 (USD BILLION)    58
FIGURE 16    GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET    59
4    PREMIUM INSIGHTS    60
4.1    CLINICAL TRIALS MARKET OVERVIEW    60
FIGURE 17    RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE
THE MARKET GROWTH    60
4.2    NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2020)    61
FIGURE 18    PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2020    61
4.3    CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICE TYPE,
2021 VS. 2026 (USD BILLION)    62
FIGURE 19    CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD    62
5    MARKET OVERVIEW    63
5.1    INTRODUCTION    63
5.2    MARKET DYNAMICS    63
FIGURE 20    CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    63
TABLE 1    CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    64
5.2.1    DRIVERS    64
5.2.1.1    Increasing investment in pharmaceutical R&D    64
FIGURE 21    INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026    65
FIGURE 22    ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021    65
5.2.1.2    Increasing number of clinical trials    66
FIGURE 23    NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)    66
5.2.1.3    High cost of in-house drug development    66
FIGURE 24    AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)    67
5.2.1.4    Rising prevalence of orphan and rare diseases    67
5.2.2    OPPORTUNITIES    68
5.2.2.1    Growth in drugs and biologics market despite COVID-19 pandemic    68
FIGURE 25    TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020)    68
TABLE 2    LIST OF BIOLOGICS APPROVED BY US FDA, 2020    68
5.2.2.2    Rising demand for specialized testing services among end users    69
5.2.2.3    Need for novel clinical trial designs for complex cell and gene therapies    70
5.2.3    CHALLENGES    70
5.2.3.1    Shortage of skilled professionals for clinical trials    70
5.2.3.2    Requirement of unique analytical testing approaches for innovative drug molecules    70
5.2.4    MARKET TRENDS    71
5.2.4.1    Adoption of artificial intelligence-based tools for drug discovery    71
5.2.4.2    Increasing outsourcing activities in emerging Asian economies    71
5.2.4.3    Integrated end-to-end R&D service solutions    73
5.3    RANGES/SCENARIOS    73
FIGURE 26    SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CLINICAL TRIALS MARKET    73
5.4    IMPACT OF COVID-19 ON CLINICAL TRIALS MARKET    74
5.5    PORTER’S FIVE FORCES ANALYSIS    75
TABLE 3    CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS    75
5.5.1    THREAT OF NEW ENTRANTS    75
5.5.2    THREAT OF SUBSTITUTES    75
5.5.3    BARGAINING POWER OF BUYERS    75
5.5.4    BARGAINING POWER OF SUPPLIERS    76
5.5.5    DEGREE OF COMPETITION    76
5.6    TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS    76
FIGURE 27    REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS    76
5.7    ECOSYSTEM ANALYSIS    77
FIGURE 28    ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET    77
TABLE 4    SUPPLY CHAIN ECOSYSTEM    78
5.8    REGULATORY ANALYSIS    79
6    CLINICAL TRIALS MARKET, BY PHASE    82
6.1    INTRODUCTION    83
TABLE 5    CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    83
FIGURE 29    DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020    84
6.2    CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION    84
FIGURE 30    CLINICAL TRIAL PLANNING & DESIGNING    84
6.3    PHASE I    87
6.3.1    ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT    87
TABLE 6    EXAMPLES OF PHASE I STUDY OF DRUGS    87
TABLE 7    PHASE I CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)    88
TABLE 8    NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    88
TABLE 9    EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    88
TABLE 10    ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    89
6.4    PHASE II    89
6.4.1    LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS    89
TABLE 11    EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES    89
TABLE 12    PHASE II CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)    90
TABLE 13    NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    90
TABLE 14    EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    91
TABLE 15    ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    91
6.5    PHASE III    92
6.5.1    RISING COSTS OF PHASE III TRIALS INCREASES THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES    92
TABLE 16    EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY    92
TABLE 17    PHASE III CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)    93
TABLE 18    NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    93
TABLE 19    EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    93
TABLE 20    ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    94
6.6    PHASE IV    94
6.6.1    RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH    94
TABLE 21    EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES    94
TABLE 22    PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)    95
TABLE 23    NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    95
TABLE 24    EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    95
TABLE 25    ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    96
7    CLINICAL TRIALS MARKET, BY SERVICE TYPE    97
7.1    INTRODUCTION    98
TABLE 26    CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)    98
7.2    PROTOCOL DESIGNING    99
7.2.1    PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES    99
TABLE 27    PROTOCOL DESIGNING MARKET, BY REGION, 2019–2026 (USD BILLION)    99
TABLE 28    NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    100
TABLE 29    EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    100
TABLE 30    ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    100
7.3    SITE IDENTIFICATION    101
7.3.1    NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY    101
TABLE 31    SITE IDENTIFICATION MARKET, BY REGION, 2019–2026 (USD BILLION)    101
TABLE 32    NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    102
TABLE 33    EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    102
TABLE 34    ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    102
7.4    PATIENT RECRUITMENT    103
7.4.1    GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT    103
TABLE 35    SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS    103
TABLE 36    PATIENT RECRUITEMENT MARKET, BY REGION, 2019–2026 (USD BILLION)    104
TABLE 37    NORTH AMERICA: PATIENT RECRUITEMENT MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    104
TABLE 38    EUROPE: PATIENT RECRUITEMENT MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    104
TABLE 39    ASIA PACIFIC: PATIENT RECRUITEMENT MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    105
7.5    LABORATORY SERVICES    105
7.5.1    INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT    105
TABLE 40    EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS    105
TABLE 41    LABORATORY SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)    106
TABLE 42    NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    106
TABLE 43    EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    107
TABLE 44    ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    107
7.5.2    ANALYTICAL TESTING SERVICES    107
7.5.2.1    Increasing demand for analytical testing for drug development to drive the growth of this segment    107
TABLE 45    ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    108
TABLE 46    NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    108
TABLE 47    EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    108
TABLE 48    ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    109
7.6    BIOANALYTICAL TESTING SERVICES    109
7.6.1    HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT    109
TABLE 49    BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD BILLION)    110
TABLE 50    BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    110
TABLE 51    NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    110
TABLE 52    EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    111
TABLE 53    ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    111
7.6.2    CELL-BASED ASSAYS    111
7.6.2.1    Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment    111
TABLE 54    CELL-BASED ASSAYS MARKET, BY REGION, 2019–2026 (USD BILLION)    112
TABLE 55    NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    112
TABLE 56    EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    112
TABLE 57    ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    113
7.6.3    VIROLOGY TESTING    113
7.6.3.1    Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment    113
TABLE 58    VIROLOGY TESTING MARKET, BY REGION, 2019–2026 (USD BILLION)    113
TABLE 59    NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    114
TABLE 60    EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    114
TABLE 61    ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    114
7.6.4    PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES    115
7.6.4.1    Rising importance of studies to determine pharmacokinetic behavior of drug candidates to drive the growth of this segment    115
TABLE 62    PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)    115
TABLE 63    NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    116
TABLE 64    EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    116
TABLE 65    ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    116
7.6.5    METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION    117
7.6.5.1    Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment    117
TABLE 66    METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET,
BY REGION, 2019–2026 (USD BILLION)    117
TABLE 67    NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    118
TABLE 68    EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    118
TABLE 69    ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    118
7.6.6    SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES    119
7.6.6.1    High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth    119
TABLE 70    SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET,
BY REGION, 2019–2026 (USD BILLION)    119
TABLE 71    NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    120
TABLE 72    EUROPE: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    120
TABLE 73    ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    120
7.6.7    BIOMARKER TESTING SERVICES    121
7.6.7.1    Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth    121
TABLE 74    BIOMARKER TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    121
TABLE 75    NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    121
TABLE 76    EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    122
TABLE 77    ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    122
7.6.8    OTHER BIOANALYTICAL TESTING SERVICES    122
TABLE 78    OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    123
TABLE 79    NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    123
TABLE 80    EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    123
TABLE 81    ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    124
7.7    CLINICAL TRIAL DATA MANAGEMENT SERVICES    124
7.7.1    DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD
THE HIGHEST CAGR DURING THE FORECAST PERIOD    124
TABLE 82    EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS    124
TABLE 83    CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    125
TABLE 84    NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    126
TABLE 85    EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    126
TABLE 86    ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    126
7.8    CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES    127
7.8.1    ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT    127
TABLE 87    CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    127
TABLE 88    NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    127
TABLE 89    EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    128
TABLE 90    ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    128
7.9    DECENTRALIZED CLINICAL TRIAL SERVICES    128
7.9.1    THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS    128
TABLE 91    DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    129
TABLE 92    NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    129
TABLE 93    EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    129
TABLE 94    ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    130
7.10    MEDICAL DEVICE TESTING SERVICES    130
7.10.1    INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET    130
TABLE 95    MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    131
TABLE 96    NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD BILLION)    131
TABLE 97    EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    131
TABLE 98    ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    132
7.11    OTHER CLINICAL TRIAL SERVICES    132
7.11.1    OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES    132
TABLE 99    OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION,
2019–2026 (USD BILLION)    133
TABLE 100    NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    133
TABLE 101    EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    133
TABLE 102    ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)    134
8    CLINICAL TRIALS MARKET, BY THERAPY AREA    135
8.1    INTRODUCTION    136
TABLE 103    CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION)    136
8.2    ONCOLOGY    136
8.2.1    RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH    136
FIGURE 31    GLOBAL CANCER INCIDENCE, BY TYPE (2020)    137
FIGURE 32    ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND)    138
TABLE 104    LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)    138
TABLE 105    CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION,
2019–2026 (USD BILLION)    139
TABLE 106    NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)    139
TABLE 107    EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY,
2019–2026 (USD BILLION)    140
TABLE 108    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)    140
8.3    INFECTIOUS DISEASES    140
8.3.1    INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD    140
TABLE 109    CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2019–2026 (USD BILLION)    141
TABLE 110    NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION)    141
TABLE 111    EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION)    142
TABLE 112    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION)    142
8.4    NEUROLOGY    142
8.4.1    INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH    142
TABLE 113    LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)    143
TABLE 114    CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION,
2019–2026 (USD BILLION)    144
TABLE 115    NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION)    144
TABLE 116    EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY,
2019–2026 (USD BILLION)    144
TABLE 117    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION)    145
8.5    IMMUNOLOGY    145
8.5.1    GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES    145
TABLE 118    CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION,
2019–2026 (USD BILLION)    145
TABLE 119    NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2019–2026 (USD BILLION)    146
TABLE 120    EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2019–2026 (USD BILLION)    146
TABLE 121    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)    146
8.6    CARDIOLOGY    147
8.6.1    HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS    147
TABLE 122    LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)    147
TABLE 123    CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION,
2019–2026 (USD BILLION)    148
TABLE 124    NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)    148
TABLE 125    EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY,
2019–2026 (USD BILLION)    148
TABLE 126    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION)    149
8.7    GENETIC DISEASES    149
8.7.1    PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH    149
TABLE 127    CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION,
2019–2026 (USD BILLION)    150
TABLE 128    NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION)    150
TABLE 129    EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)    150
TABLE 130    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES,
BY COUNTRY, 2019–2026 (USD BILLION)    151
8.8    WOMEN’S HEALTH    151
8.8.1    RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO DRIVE MARKET GROWTH    151
TABLE 131    CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION,
2019–2026 (USD BILLION)    151
TABLE 132    NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH,
BY COUNTRY, 2019–2026 (USD BILLION)    152
TABLE 133    EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD BILLION)    152
TABLE 134    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH,
BY COUNTRY, 2019–2026 (USD BILLION)    152
8.9    OTHER THERAPY AREAS    153
FIGURE 33    ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,
2000-2045 (MILLION)    153
TABLE 135    LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)    154
TABLE 136    CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY REGION,
2019–2026 (USD BILLION)    154
TABLE 137    NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2019–2026 (USD BILLION)    155
TABLE 138    EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2019–2026 (USD BILLION)    155
TABLE 139    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2019–2026 (USD BILLION)    155
9    CLINICAL TRIALS MARKET, BY APPLICATION    156
9.1    INTRODUCTION    157
TABLE 140    CLINICAL TRIAL MARKET, BY APPLICATION, 2019–2026 (USD BILLION)    157
9.2    SMALL MOLECULE    157
9.2.1    INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS
THE GROWTH OF THIS SEGMENT    157
FIGURE 34    SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019    158
TABLE 141    CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION,
2019–2026 (USD BILLION)    158
TABLE 142    NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION)    159
TABLE 143    EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION)    159
TABLE 144    ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2019–2026 (USD BILLION)    159
9.3    VACCINES    160
9.3.1    OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON
THE INDUSTRY OPERATIONS    160
FIGURE 35    COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT,
BY PHASE (AS OF JANUARY 2022)    161
TABLE 145    CLINICAL TRIALS MARKET FOR VACCINES, BY REGION,
2019–2026 (USD BILLION)    161
TABLE 146    NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION)    161
TABLE 147    EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION)    162
TABLE 148    ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION)    162
9.4    CELL & GENE THERAPY    162
9.4.1    THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND THEIR RESPECTIVE OFFERINGS IS DRIVING THE CLINICAL DEVELOPMENT PIPELINE FOR CELL & GENE THERAPY    162
FIGURE 36    ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY,
BY INDICATION (AS OF 2020)    163
FIGURE 37    ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020)    164
TABLE 149    CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION,
2019–2026 (USD BILLION)    164
TABLE 150    NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION)    165
TABLE 151    EUROPE: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION)    165
TABLE 152    ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION)    165
9.5    OTHER APPLICATIONS    166
9.5.1    INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH    166
TABLE 153    CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD BILLION)    166
TABLE 154    NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)    167
TABLE 155    EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)    167
TABLE 156    ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)    167
10    CLINICAL TRIALS MARKET, BY REGION    168
10.1    INTRODUCTION    169
TABLE 157    CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION)    169
10.2    NORTH AMERICA    169
FIGURE 38    NORTH AMERICA SNAPSHOT    170
TABLE 158    NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    170
TABLE 159    NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE,
2019–2026 (USD BILLION)    171
TABLE 160    NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET,
BY SERVICE TYPE, 2019–2026 (USD BILLION)    171
TABLE 161    NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET,
BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)    172
TABLE 162    NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET,
BY THERAPY AREA, 2019–2026 (USD BILLION)    172
TABLE 163    NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    173
10.2.1    US    173
10.2.1.1    Robust clinical research activities to become a key factor supporting the US market growth    173
FIGURE 39    US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES
BY REGION (2020 VS. 2019)    174
TABLE 164    US: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    174
TABLE 165    US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)    175
TABLE 166    US: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    175
TABLE 167    US: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    176
TABLE 168    US: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)    176
10.2.2    CANADA    176
10.2.2.1    Increasing number of clinical trials in Canada to support market growth    176
TABLE 169    CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    177
TABLE 170    CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    177
TABLE 171    CANADA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    178
TABLE 172    CANADA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    178
TABLE 173    CANADA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    179

10.3    EUROPE    179
FIGURE 40    CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)    180
TABLE 174    EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    180
TABLE 175    EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    180
TABLE 176    EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    181
TABLE 177    EUROPE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    181
TABLE 178    EUROPE: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    182
TABLE 179    EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    182
10.3.1    GERMANY    182
10.3.1.1    Government support and flexible labor laws have made Germany a favorable location for clinical trials    182
TABLE 180    GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    183
TABLE 181    GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    183
TABLE 182    GERMANY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    184
TABLE 183    GERMANY: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    184
TABLE 184    GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    185
10.3.2    UK    185
10.3.2.1    Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth    185
FIGURE 41    UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017 (USD MILLION)    186
TABLE 185    UK: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    186
TABLE 186    UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION)    187
TABLE 187    UK: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    187
TABLE 188    UK: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    188
TABLE 189    UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)    188
10.3.3    FRANCE    188
10.3.3.1    High number of oncology clinical trials in France is expected to drive market growth in France    188
TABLE 190    FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    189
TABLE 191    FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    189
TABLE 192    FRANCE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    190
TABLE 193    FRANCE: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    190
TABLE 194    FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    191
10.3.4    ITALY    191
10.3.4.1    Low drug approval times along with the growing number of clinical trials in Italy to drive market growth    191
TABLE 195    NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)    191
TABLE 196    ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    192
TABLE 197    ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    192
TABLE 198    ITALY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    193
TABLE 199    ITALY: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    193
TABLE 200    ITALY: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    194
10.3.5    SPAIN    194
10.3.5.1    Rising R&D expenditure to boost market growth for clinical trials
in Spain    194
FIGURE 42    SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011–2017    195
TABLE 201    SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    195
TABLE 202    SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    196
TABLE 203    SPAIN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    196
TABLE 204    SPAIN: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    197
TABLE 205    SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    197
10.3.6    REST OF EUROPE (ROE)    198
TABLE 206    ROE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    199
TABLE 207    ROE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    199
TABLE 208    ROE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    200
TABLE 209    ROE: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    200
TABLE 210    ROE: CLINICAL TRIALS MARKET, BY MOLECULE, 2019–2026 (USD BILLION)    201"
"10.4    ASIA PACIFIC (APAC)    201
FIGURE 43    ASIA PACIFIC SNAPSHOT    202
TABLE 211    ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY,
2019–2026 (USD BILLION)    202
TABLE 212    ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE,
2019–2026 (USD BILLION)    203
TABLE 213    ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    203
TABLE 214    ASIA PACIFIC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)    204
TABLE 215    ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    204
TABLE 216    ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    205
10.4.1    CHINA    205
10.4.1.1    China dominates the clinical trials services market owing to a robust pharmaceutical industry and presence of prominent clinical trial service providers    205
TABLE 217    CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    206
TABLE 218    CHINA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    206
TABLE 219    CHINA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    207
TABLE 220    CHINA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    207
TABLE 221    CHINA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    208
10.4.2    JAPAN    208
10.4.2.1    Strong focus on R&D activities in Japan is expected to drive market growth    208
TABLE 222    TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA,
2017 VS. 2019    208
TABLE 223    JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    209
TABLE 224    JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    209
TABLE 225    JAPAN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    210
TABLE 226    JAPAN: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    210
TABLE 227    JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    211
10.4.3    INDIA    211
10.4.3.1    Growing pharmaceutical industry in India to drive the market growth for clinical trails    211
TABLE 228    TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA,
2017 VS. 2019    211
TABLE 229    INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    212
TABLE 230    INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    212
TABLE 231    INDIA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    213
TABLE 232    INDIA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    213
TABLE 233    INDIA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    214
10.4.4    REST OF ASIA PACIFIC    214
TABLE 234    TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA,
BY THERAPEUTIC AREA, 2017 VS. 2019    214
TABLE 235    ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    215
TABLE 236    ROAPAC: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    215
TABLE 237    ROAPAC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    216
TABLE 238    ROAPAC: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    216
TABLE 239    ROAPAC: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    217
10.5    LATIN AMERICA    217
10.5.1    GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET
GROWTH IN LATIN AMERICA    217
TABLE 240    LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE,
2019–2026 (USD BILLION)    218
TABLE 241    LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    218
TABLE 242    LATIN AMERICA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION)    219
TABLE 243    LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    219
TABLE 244    LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    220
10.6    MIDDLE EAST & AFRICA    220
10.6.1    GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA    220
TABLE 245    MEA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION)    221
TABLE 246    MEA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,
2019–2026 (USD BILLION)    221
TABLE 247    MEA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,
2019–2026 (USD BILLION)    222
TABLE 248    MEA: CLINICAL TRIALS MARKET, BY THERAPY AREA,
2019–2026 (USD BILLION)    222
TABLE 249    MEA: CLINICAL TRIALS MARKET, BY APPLICATION,
2019–2026 (USD BILLION)    223
11    COMPETITIVE LANDSCAPE    224
11.1    INTRODUCTION    224
11.2    RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS    224
FIGURE 44    CLINICAL TRIALS MARKET: STRATEGIES ADOPTED    225
11.3    MARKET SHARE ANALYSIS    226
FIGURE 45    CLINICAL TRIALS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)    226
11.4    COMPANY EVALUATION QUADRANT    228
11.4.1    STARS    228
11.4.2    EMERGING LEADERS    228
11.4.3    PERVASIVE PLAYERS    228
11.4.4    PARTICIPANTS    228
FIGURE 46    CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2020    229
11.5    COMPETITIVE BENCHMARKING    230
11.5.1    COMPANY SERVICE FOOTPRINT (20 COMPANIES)    230
FIGURE 47    SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET    230
11.5.2    COMPANY REGIONAL FOOTPRINT (20 COMPANIES)    231
FIGURE 48    REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET    231
11.6    COMPETITIVE SCENARIO AND TRENDS    232
11.6.1    SERVICES LAUNCHES    232
TABLE 250    CLINICAL TRIALS MARKET: SERVICE LAUNCHES
(JANUARY 2017-NOVEMBER 2020)    232
11.6.2    DEALS    233
TABLE 251    CLINICAL TRIALS MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021)    233
11.6.3    OTHER DEVELOPMENTS    234
TABLE 252    CLINICAL TRIALS MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020)    234
12    COMPANY PROFILES    235
12.1    KEY COMPANIES    235
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1    IQVIA    235
TABLE 253    IQVIA: BUSINESS OVERVIEW    235
FIGURE 49    IQVIA: COMPANY SNAPSHOT    236
TABLE 254    IQVIA: SERVICE OFFERINGS    236
TABLE 255    IQVIA: SERVICE LAUNCHES    237
TABLE 256    IQVIA: DEALS    238
TABLE 257    IQVIA: OTHER DEVELOPMENTS    238
12.1.2    LABCORP DRUG DEVELOPMENT (COVANCE)    240
TABLE 258    LABCORP: BUSINESS OVERVIEW    240
FIGURE 50    LABCORP: COMPANY SNAPSHOT    241
TABLE 259    LABCORP: SERVICE OFFERINGS    241
TABLE 260    LABCORP: SERVICE LAUNCHES    242
TABLE 261    LABCORP: DEALS    243
TABLE 262    LABCORP: EXPANSIONS    244
12.1.3    SYNEOS HEALTH INC.    246
TABLE 263    SYNEOS HEALTH INC.: BUSINESS OVERVIEW    246
FIGURE 51    SYNEOS HEALTH INC.: COMPANY SNAPSHOT    246
TABLE 264    SYNEOS HEALTH INC.: SERVICE OFFERINGS    247
TABLE 265    SYNEOS HEALTH INC: SERVICE LAUNCHES    248
TABLE 266    SYNEOS HEALTH INC.: DEALS    248
12.1.4    WUXI APPTEC    252
TABLE 267    WUXI APPTEC: BUSINESS OVERVIEW    252
FIGURE 52    WUXI APPTEC: COMPANY SNAPSHOT    253
TABLE 268    WUXI APPTEC: SERVICE OFFERINGS    253
TABLE 269    WUXI APPTEC: SERVICE LAUNCHES    255
TABLE 270    WUXI APPTEC: DEALS    256
TABLE 271    WUXI APPTEC: EXPANSIONS    257
12.1.5    CHARLES RIVER LABORATORIES    259
TABLE 272    CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW    259
FIGURE 53    CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT    260
TABLE 273    CHARLES RIVER LABORATORIES: SERVICE OFFERINGS    260
TABLE 274    CHARLES RIVER LABORATORIES: DEALS    261
TABLE 275    CHARLES RIVER LABORATORIES: EXPANSIONS    263
12.1.6    PAREXEL INTERNATIONAL    265
TABLE 276    PAREXEL INTERNATIONAL: BUSINESS OVERVIEW    265
TABLE 277    PAREXEL INTERNATIONAL: SERVICE OFFERINGS    265
TABLE 278    PAREXEL INTERNATIONAL: SERVICE LAUNCHES    267
TABLE 279    PAREXEL INTERNATIONAL: DEALS    268
TABLE 280    PAREXEL INTERNATIONAL: EXPANSIONS    270
12.1.7    PRA HEALTH SCIENCES    271
TABLE 281    PRA HEALTH SCIENCES: BUSINESS OVERVIEW    271
FIGURE 54    PRA HEALTH SCIENCES: COMPANY SNAPSHOT    272
TABLE 282    PRA HEALTH SCIENCES: SERVICE OFFERINGS    272
TABLE 283    PRA HEALTH SCIENCES: SERVICE LAUNCHES    272
TABLE 284    PRA HEALTH SCIENCES: DEALS    273
TABLE 285    PRA HEALTH SCIENCES: EXPANSIONS    274
12.1.8    PPD INC    275
TABLE 286    PPD INC: BUSINESS OVERVIEW    275
FIGURE 55    PPD INC: COMPANY SNAPSHOT    276
TABLE 287    PPD INC: SERVICE OFFERINGS    276
TABLE 288    PPD: SERVICE LAUNCHES    277
TABLE 289    PPD: DEALS    278
TABLE 290    PPD: EXPANSIONS    280
12.1.9    ICON PLC    281
TABLE 291    ICON PLC: BUSINESS OVERVIEW    281
FIGURE 56    ICON PLC: COMPANY SNAPSHOT    281
TABLE 292    ICON PLC: SERVICE OFFERINGS    282
TABLE 293    ICON PLC : SERVICE LAUNCHES    285
TABLE 294    ICON PLC: DEALS    285
12.1.10    MEDPACE HOLDINGS INC    287
TABLE 295    MEDPACE HOLDINGS INC: BUSINESS OVERVIEW    287
FIGURE 57    MEDPACE HOLDINGS INC: COMPANY SNAPSHOT    287
TABLE 296    MEDPACE HOLDINGS INC: SERVICE OFFERINGS    288
TABLE 297    MEDPACE HOLDINGS INC: DEALS    288
TABLE 298    MEDPACE HOLDINGS INC: EXPANSION    288
12.1.11    ACM GLOBAL LABORATORIES    289
TABLE 299    ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW    289
TABLE 300    ACM GLOBAL LABORATORIES: SERVICE OFFERINGS    289
12.1.12    ADVANCED CLINICAL    291
TABLE 301    ADVANCED CLINICAL: BUSINESS OVERVIEW    291
TABLE 302    ADVANCED CLINICAL: SERVICE OFFERINGS    291
12.1.13    SGS    293
TABLE 303    SGS: BUSINESS OVERVIEW    293
FIGURE 58    SGS: COMPANY SNAPSHOT    294
TABLE 304    SGS: SERVICE OFFERINGS    294
TABLE 305    SGS: DEALS    295
12.1.14    FRONTAGE HOLDINGS CORPORATION    296
TABLE 306    FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW    296
FIGURE 59    FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT    297
TABLE 307    FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS    297
TABLE 308    FRONTAGE HOLDINGS CORPORATION: DEALS    298
TABLE 309    FRONTAGE HOLDINGS CORPORATION: EXPANSION    299
12.1.15    PSI CRO AG    300
TABLE 310    PSI CRO AG: BUSINESS OVERVIEW    300
TABLE 311    PSI CRO AG: SERVICE OFFERINGS    300
TABLE 312    PSI CRO AG: EXPANSIONS    300
12.1.16    BIO AGILE THERAPEUTICS    301
TABLE 313    BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW    301
TABLE 314    BIO AGILE THERAPEUTICS: SERVICE OFFERINGS    301
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2    OTHER PLAYERS    303
12.2.1    AZELIX    303
TABLE 315    AZELIX: COMPANY OVERVIEW    303
12.2.2    CTSERV    304
TABLE 316    CTSERV: COMPANY OVERVIEW    304
12.2.3    PEPGRA    304
TABLE 317    PEPGRA: COMPANY OVERVIEW    304
12.2.4    AXCENT ADVANCED ANALYTICS (A3)    305
TABLE 318    AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW    305
12.2.5    DOVE QUALITY SOLUTIONS    306
TABLE 319    DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW    306
12.2.6    FIRMA CLINICAL RESEARCH    306
TABLE 320    FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW    306
12.2.7    CELERION    307
TABLE 321    CELERION: COMPANY OVERVIEW    307
12.2.8    NOVOTECH HEALTH HOLDINGS    308
TABLE 322    NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW    308
12.2.9    GENETICIST INC.    308
TABLE 323    GENETICIST INC.: COMPANY OVERVIEW    308
12.2.10    LINICAL AMERICAS    309
TABLE 324    LINICAL AMERICAS: COMPANY OVERVIEW    309
13    APPENDIX    310
13.1    DISCUSSION GUIDE    310
13.2    KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    313
13.3    AVAILABLE CUSTOMIZATIONS    315
13.4    RELATED REPORT    316
13.5    AUTHOR DETAILS    317"